Nonalcoholic Fatty Liver Disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. The effects of time-restricted eating for patients with nonalcoholic fatty liver disease: a systematic review.Frontiers in nutrition · 2023
   Pooled it
2. The impacts of Ramadan fasting for patients with non-alcoholic fatty liver disease (NAFLD): a systematic review.Frontiers in nutrition · 2023
   Pooled it
3. A combined extract containingFood science and biotechnology · 2024
   Article
4. Follicle-stimulating hormone is negatively associated with nonalcoholic fatty liver disease in a Chinese elderly population: a retrospective observational study.BMC endocrine disorders · 2023
   Observational

Corrections and comments

• Commented on by
  Nonalcoholic Fatty Liver Disease. Reply.2022
• Comment on
  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.2021
• Comment on
  Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.2021

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as